A detailed history of Cowen And Company, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Cowen And Company, LLC holds 3,244,498 shares of STOK stock, worth $39 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares
3,244,498
Previous 3,365,744 3.6%
Holding current value
$39 Million
Previous $45.5 Million 12.31%
% of portfolio
1.03%
Previous 1.16%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$12.24 - $15.92 $1.48 Million - $1.93 Million
-121,246 Reduced 3.6%
3,244,498 $39.9 Million
Q1 2024

May 03, 2024

SELL
$4.12 - $14.17 $1.47 Million - $5.04 Million
-355,915 Reduced 9.56%
3,365,744 $45.4 Million
Q4 2023

Feb 12, 2024

BUY
$3.37 - $5.4 $12.5 Million - $20.1 Million
3,721,659 New
3,721,659 $19.6 Million
Q2 2023

Aug 07, 2023

BUY
$7.93 - $13.82 $3.51 Million - $6.12 Million
442,517 Added 13.49%
3,721,659 $39.6 Million
Q1 2023

May 09, 2023

BUY
$7.65 - $10.38 $19.4 Million - $26.3 Million
2,531,065 Added 338.34%
3,279,142 $27.3 Million
Q4 2022

Feb 09, 2023

SELL
$7.07 - $15.69 $149,120 - $330,933
-21,092 Reduced 2.74%
748,077 $6.9 Million
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $9.3 Million - $16.7 Million
-740,451 Reduced 49.05%
769,169 $9.88 Million
Q2 2022

Aug 05, 2022

BUY
$10.36 - $23.93 $922,972 - $2.13 Million
89,090 Added 6.27%
1,509,620 $19.9 Million
Q1 2022

May 16, 2022

BUY
$17.19 - $26.1 $19.3 Million - $29.4 Million
1,125,105 Added 380.84%
1,420,530 $29.9 Million
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $4.7 Million - $7.97 Million
259,526 Added 722.93%
295,425 $6.84 Million
Q3 2021

Nov 12, 2021

BUY
$23.65 - $34.44 $849,011 - $1.24 Million
35,899 New
35,899 $913,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $474M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.